| 000 | 02962 a2200829 4500 | ||
|---|---|---|---|
| 005 | 20250516195219.0 | ||
| 264 | 0 | _c20140408 | |
| 008 | 201404s 0 0 eng d | ||
| 022 | _a1878-3686 | ||
| 024 | 7 |
_a10.1016/j.ccr.2014.01.009 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChoi, Woonyoung | |
| 245 | 0 | 0 |
_aIdentification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. _h[electronic resource] |
| 260 |
_bCancer cell _cFeb 2014 |
||
| 300 |
_a152-65 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aCarcinoma, Basal Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 | _aCell Differentiation |
| 650 | 0 | 4 | _aCell Proliferation |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Profiling |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 |
_aMicroRNAs _xgenetics |
| 650 | 0 | 4 |
_aMuscle Neoplasms _xclassification |
| 650 | 0 | 4 |
_aMutation _xgenetics |
| 650 | 0 | 4 | _aNeoadjuvant Therapy |
| 650 | 0 | 4 | _aNeoplasm Invasiveness |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPPAR gamma _xgenetics |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 | _aReal-Time Polymerase Chain Reaction |
| 650 | 0 | 4 |
_aReceptor, Fibroblast Growth Factor, Type 3 _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xgenetics |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xgenetics |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xclassification |
| 650 | 0 | 4 |
_aVinblastine _xadministration & dosage |
| 700 | 1 | _aPorten, Sima | |
| 700 | 1 | _aKim, Seungchan | |
| 700 | 1 | _aWillis, Daniel | |
| 700 | 1 | _aPlimack, Elizabeth R | |
| 700 | 1 | _aHoffman-Censits, Jean | |
| 700 | 1 | _aRoth, Beat | |
| 700 | 1 | _aCheng, Tiewei | |
| 700 | 1 | _aTran, Mai | |
| 700 | 1 | _aLee, I-Ling | |
| 700 | 1 | _aMelquist, Jonathan | |
| 700 | 1 | _aBondaruk, Jolanta | |
| 700 | 1 | _aMajewski, Tadeusz | |
| 700 | 1 | _aZhang, Shizhen | |
| 700 | 1 | _aPretzsch, Shanna | |
| 700 | 1 | _aBaggerly, Keith | |
| 700 | 1 | _aSiefker-Radtke, Arlene | |
| 700 | 1 | _aCzerniak, Bogdan | |
| 700 | 1 | _aDinney, Colin P N | |
| 700 | 1 | _aMcConkey, David J | |
| 773 | 0 |
_tCancer cell _gvol. 25 _gno. 2 _gp. 152-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ccr.2014.01.009 _zAvailable from publisher's website |
| 999 |
_c23543407 _d23543407 |
||